67305-69-5

Basic information

• Product Name: 2,6-Morpholinedione, 4-(phenylmethyl)-
• CAS NO: 67305-69-5
• Molecular Formula: C11H11NO3
• Molecular Weight: 205.213
• Mol File: 67305-69-5.mol
• Article Data: 4

Chemical Properties

• CAS DataBase Reference: 2,6-Morpholinedione, 4-(phenylmethyl)-(CAS DataBase Reference)
• NIST Chemistry Reference: 2,6-Morpholinedione, 4-(phenylmethyl)-(67305-69-5)
• EPA Substance Registry System: 2,6-Morpholinedione, 4-(phenylmethyl)-(67305-69-5)

Safety Data

• Hazardous Substances Data: 67305-69-5(Hazardous Substances Data)

Upstream product

• 100-39-0 benzyl bromide 
• 3987-53-9 N-benzyliminodiacetic acid 

Downstream Products

• 1333226-73-5 (S)-2-[2-(benzyl-carboxymethyl-amino)-acetylamino]-3-(1H-imidazol-4-yl)-propionic acid methyl ester 
• 1333228-02-6 (S)-2-(2-(benzyl-carboxymethyl-amino)-acetylamino)-3-phenyl-propionic acid methyl ester 
• 1333227-64-7 (benzyl-{[(S)-2-(1H-imidazol-4-yl)-1-methylcarbamoyl-ethylcarbamoyl]-methyl}-amino)-acetic acid. 
• 1333226-97-3 C₃₇H₃₆N₄O₅ 
• 1333228-01-5 (S)-2-[2-(Benzyl-carboxymethyl-amino)-acetylamino]-3-(1H-indol-3-yl)-propionic acid methyl ester 
• 1333226-74-6 BDM₄₁₃₆₇ 
• 1333227-17-0 (S)-2-[2-(Benzyl-carboxymethyl-amino)-acetylamino]-3-(1-trityl-1H-imidazol-4-yl)-propionic acid tert-butyl ester 
• 1333227-55-6 CH₂O₂*C₂₁H₂₈N₄O₅ 

Relevant articles and documents

4-BENZYL-1-PHENETHYL-PIPERAZINE-2,6-DIONE PREPARATION METHOD, AND INTERMEDIATE AND PREPARATION METHOD THEREOF

The present invention provides a key new intermediate (a compound of formula III) of 4-benzyl-1-phenethyl-piperazine-2,6-dione (formula IV compound), a pharmaceutically acceptable salt thereof and a preparation method thereof. The present invention additi

Imidazole-derived 2-[N-carbamoylmethyl-alkylamino]acetic acids, substrate-dependent modulators of insulin-degrading enzyme in amyloid-β hydrolysis

Insulin degrading enzyme (IDE) is a highly conserved zinc metalloprotease that is involved in the clearance of various physiologically peptides like amyloid-beta and insulin. This enzyme has been involved in the physiopathology of diabetes and Alzheimer's disease. We describe here a series of small molecules discovered by screening. Co-crystallization of the compounds with IDE revealed a binding both at the permanent exosite and at the discontinuous, conformational catalytic site. Preliminary structure-activity relationships are described. Selective inhibition of amyloid-beta degradation over insulin hydrolysis was possible. Neuroblastoma cells treated with the optimized compound display a dose-dependent increase in amyloid-beta levels.